Treatment with stem cells, a new era in medical science.......

A new Era is coming forward in the treatment of human body. That is the STEM CELL THERAPY. If this treatment comes forward then medical science can treat many of those major diseases that are killing a large number of people each year. There are many diseases now that can't be cured by medical treatment, like Paralysis. If a patient has paralysis then doctors give him only some supportive treatment to improve his nerve supply on that affected area. But it can't give a redical cure. Because if a nerve cell damaged it cant be regenerated due to it is mane if stable cells. But, if a stem cell is replaced on that area then it can regenerate a nerve cell because stem cell can grow in the form of any cells or tissues, it has that capacity. Although a stem cell can grow in any form of a tissue or an organ. So, if we can place a stem cell in that affected hand or leg then this stem cell will grow under control and can regenerate into that original tissue. So, the patient will be cured ultimately.
And this theory made our scientists happy. And from this theory many researches are going on under laboratory. We all hope that finally we will get a new Era on medical treatment.

Comments

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death.

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with

MEDICAL RESEARCH BANGLADESH ( BD )

Search This Blog